55666-42-7

Basic information

• Product Name: TERT-BUTYL-2-BROMOBENZOATE
• Synonyms: 2-BROMO-BENZOIC ACID TERT-BUTYL ESTER;TERT-BUTYL-2-BROMOBENZOATE
• CAS NO: 55666-42-7
• Molecular Formula: C₁₁H₁₃BrO₂
• Molecular Weight: 257.12
• Product Categories: Aryl;Ester;Organohalides
• Mol File: 55666-42-7.mol

Chemical Properties

• Boiling Point: 280.3 °C at 760 mmHg
• Flash Point: 123.3 °C
• Appearance: /
• Density: 1.331 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: TERT-BUTYL-2-BROMOBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL-2-BROMOBENZOATE(55666-42-7)
• EPA Substance Registry System: TERT-BUTYL-2-BROMOBENZOATE(55666-42-7)

Safety Data

• Hazardous Substances Data: 55666-42-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL-2-BROMOBENZOATE is used as a chemical intermediate for the synthesis of various organic compounds and pharmaceuticals. Its unique structure and properties make it a valuable component in the development of new drugs and medications.
Used in Organic Chemistry:
TERT-BUTYL-2-BROMOBENZOATE is employed as a reagent in organic chemical reactions, such as esterifications and nucleophilic substitutions. Its reactivity and stability contribute to the efficiency and selectivity of these processes.
Used in Cosmetic and Fragrance Industry:
Due to its mild, non-offensive odor, TERT-BUTYL-2-BROMOBENZOATE is used in cosmetic and fragrance products. It serves as a key ingredient in the formulation of perfumes, deodorants, and other personal care products, enhancing their scent profiles and ensuring a pleasant user experience.

Upstream product

• 115-11-7 isobutene 
• 88-65-3 2-bromobenzoic-acid 
• 75-65-0 tert-butyl alcohol 
• 75-91-2 tert.-butylhydroperoxide 
• 19472-74-3 2-(2-bromophenyl)acetonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 7154-66-7 2-bromobenzoic acid chloride 

Downstream Products

• 1333433-52-5 C₁₈H₂₄O₄ 
• 1333433-53-6 (E)-2-(3-butoxy-3-oxoprop-1-en-1-yl)benzoic acid 
• 1333433-54-7 butyl (E)-3-(2-(chlorocarbonyl)phenyl)acrylate 
• 1333433-43-4 (E)-butyl 3-(2-(methoxycarbamoyl)phenyl)acrylate 
• 1401319-70-7 2-((E)-2-ethoxycarbonylvinyl)benzoic acid tert-butyl ester 
• 115974-95-3 (E)-2-(3-methoxy-3-oxoprop-1-en-1-yl)benzoic acid 
• 1415256-25-5 tert-butyl 4'-((5-(benzyl(methyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)biphenyl-2-carboxylate 

Relevant articles and documents

Silver/manganese dioxide nanorod catalyzed hydrogen-borrowing reactions and tert-butyl ester synthesis

Silver/manganese dioxide (Ag@MnO2) nanorods are synthesized and characterized by scanning electron microscopy, transmission electron microscopy, energy dispersive X-ray spectroscopy, X-ray powder diffraction, and X-ray photoelectron spectroscopy. It was discovered that Ag@MnO2 nanorods can realize hydrogen-borrowing reactions in high yields and are also effective for the synthesis of tert-butyl esters from aryl cyanides and tert-butyl hydroperoxide in a short period of time. Mechanistic experiments revealed that this catalytic system acts as a Lewis acid in hydrogen-borrowing reactions, while the synthesis of tert-butyl esters occurs through a radical pathway. This is the first report on the excellent catalytic activity of Ag@MnO2 nanorods as a catalyst.

A Fluorescent Probe for Rapid, High-Contrast Visualization of Folate-Receptor-Expressing Tumors In Vivo

Folate receptors (FRs) are membrane proteins involved in folic acid uptake, and the alpha isoform (FR-α) is overexpressed in ovarian and endometrial cancer cells. For fluorescence imaging of FRs in vivo, the near-infrared (NIR) region (650–900 nm), in which tissue penetration is high and autofluorescence is low, is optimal, but existing NIR fluorescent probes targeting FR-α show high non-specific tissue adsorption, and require prolonged washout to visualize tumors. We have designed and synthesized a new NIR fluorescent probe, FolateSiR-1, utilizing a Si-rhodamine fluorophore having a carboxy group at the benzene moiety, coupled to a folate ligand moiety through a negatively charged tripeptide linker. This probe exhibits very low background fluorescence and afforded a tumor-to-background ratio (TBR) of up to 83 in FR-expressing tumor-bearing mice within 30 min. Thus, FolateSiR-1 has the potential to contribute to the research in the field of biology and the clinical medicine.

Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI)

Dual inhibition of angiotensin-converting enzyme (ACE) and neprilysin (NEP) by drugs such as omapatrilat produces superior antihypertensive efficacy relative to ACE inhibitors but is associated with a higher risk of life-threatening angioedema due to bradykinin elevations. We hypothesized that dual AT1 (angiotensin II type 1 receptor) blockade and NEP inhibition with a single molecule would produce similar antihypertensive efficacy to omapatrilat without the risk of angioedema since ACE (the rate limiting enzyme in bradykinin metabolism) would remain uninhibited. Merging the structures of losartan (an AT1 antagonist) and thiorphan (a NEP inhibitor) led to the discovery of a novel series of orally active, dual AT1 antagonist/NEP inhibitors (ARNIs) exemplified by compound 35 (TD-0212). In models of renin-dependent and -independent hypertension, 35 produced blood pressure reductions similar to omapatrilat and combinations of AT1 receptor antagonists and NEP inhibitors. Upper airway angioedema risk was assessed in a rat tracheal plasma extravasation (TPE) model. Unlike omapatrilat, 35 did not increase TPE at antihypertensive doses. Compound 35 therefore provides the enhanced activity of dual AT1/NEP inhibition with a potentially lower risk of angioedema relative to dual ACE/NEP inhibition.

Efficient synthesis of esters through oxone-catalyzed dehydrogenation of carboxylic acids and alcohols

Since esters are important organic synthesis intermediates, an environmentally friendly oxone catalyzed-esterification of carboxylic acids with alcohols has been developed. A series of carboxylic acid esters are obtained in high yield. This strategy requires mild reaction conditions, providing an attractive alternative for the construction of valuable carbonyl esters. Electron-rich and electron-deficient groups are compatible with the standard conditions and a variety of substrates are demonstrated. Moreover, the reaction could easily be adapted to typical prodrugs, drugs and gram-scale synthesis.

The Conversion of tert-Butyl Esters to Acid Chlorides Using Thionyl Chloride

The reaction of tert-butyl esters with SOCl2 at room temperature provides acid chlorides in unpurified yields of 89% or greater. Benzyl, methyl, ethyl, and isopropyl esters are essentially unreactive under these conditions, allowing for the selective conversion of tert-butyl esters to acid chlorides in the presence of other esters.

COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a compound inhibiting CDK5-mediated PPARG phosphorylation and a pharmaceutical composition for treating PPARG-related diseases containing the same as an active ingredient. A compound represented by formula 1 or an optical

PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

Intramolecular rearrangement of α-azidoperoxides: An efficient synthesis of tert-butyl esters

An unprecedented intramolecular rearrangement of α-azidoperoxides, promoted by simple organic base to provide tert-butyl esters, has been presented. Further, a one-pot methodology consisting of in situ generation of the α-azidoperoxides from corresponding aldehydes followed by base-promoted rearrangement to obtain the desired ester has also been executed. Relevant mechanistic studies, to provide the proof for intramolecular alkoxy transfer, are investigated.

N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPARy), inhibit cdJk5-mediated phosphorylation of PP ARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

Methods for detecting sulfhydryl-containing compounds in a biological test sample

The invention relates to methods for detecting the presence of a compound of formula I in a biological test sample: where R2, R3, and R4 are as defined in the specification; or a salt thereof.